Summary

Polycystic Ovarian Syndrome Treatment Market – Scope of Report
TMR’s report on the global polycystic ovarian syndrome treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global polycystic ovarian syndrome treatment market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global polycystic ovarian syndrome treatment market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the polycystic ovarian syndrome treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global polycystic ovarian syndrome treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global polycystic ovarian syndrome treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global polycystic ovarian syndrome treatment market.

The report delves into the competitive landscape of the global polycystic ovarian syndrome treatment market. Key players operating in the global polycystic ovarian syndrome treatment market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global polycystic ovarian syndrome treatment market profiled in this report.

Key Questions Answered in Global polycystic ovarian syndrome treatment Market Report
• What is the sales/revenue generated by polycystic ovarian syndrome treatment across all regions during the forecast period?
• What are the opportunities in the global polycystic ovarian syndrome treatment market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Polycystic Ovarian Syndrome Treatment Market – Research Objectives and Research Approach
The comprehensive report on the global polycystic ovarian syndrome treatment market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global polycystic ovarian syndrome treatment market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global polycystic ovarian syndrome treatment market.

ページTOPに戻る

Table of Contents

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Polycystic Ovarian Syndrome Treatment Market
4. Market Overview
    4.1. Introduction
        4.1.1. Product Definition
        4.1.2. Industry Evolution/Developments
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Polycystic Ovarian Syndrome Treatment Market Analysis and Forecast, 2020-2034
5. Key Insights
    5.1. Pipeline Analysis
    5.2. Key Product/Brand Analysis
    5.3. Key Mergers & Acquisitions
    5.4. COVID-19 Pandemic Impact on Industry
6. Global Polycystic Ovarian Syndrome Treatment Market Analysis and Forecast, by Drug Class
    6.1. Introduction & Definition
    6.2. Key Findings/Developments
    6.3. Market Value Forecast, by Drug Class, 2020-2034
        6.3.1. Oral Contraceptives
        6.3.2. Antiandrogens
        6.3.3. Insulin-sensitizing Agent
        6.3.4. Antidepressant
        6.3.5. Anti-obesity
        6.3.6. Diuretics
        6.3.7. Others
    6.4. Market Attractiveness Analysis, by Drug Class
7. Global Polycystic Ovarian Syndrome Treatment Market Analysis and Forecast, by Distribution Channel
    7.1. Introduction & Definition
    7.2. Key Findings/Developments
    7.3. Market Value Forecast, by Distribution Channel, 2020-2034
        7.3.1. Hospital Pharmacies
        7.3.2. Retail Pharmacies
        7.3.3. Online Pharmacies
    7.4. Market Attractiveness Analysis, by Distribution Channel
8. Global Polycystic Ovarian Syndrome Treatment Market Analysis and Forecast, by Region
    8.1. Key Findings
    8.2. Market Value Forecast, by Region, 2020-2034
        8.2.1. North America
        8.2.2. Europe
        8.2.3. Asia Pacific
        8.2.4. Latin America
        8.2.5. Middle East & Africa
    8.3. Market Attractiveness Analysis, by Region
9. North America Polycystic Ovarian Syndrome Treatment Market Analysis and Forecast
    9.1. Introduction
    9.2. Key Findings
    9.3. Market Value Forecast, by Drug Class, 2020-2034
        9.3.1. Oral Contraceptives
        9.3.2. Antiandrogens
        9.3.3. Insulin-sensitizing Agent
        9.3.4. Antidepressant
        9.3.5. Anti-obesity
        9.3.6. Diuretics
        9.3.7. Others
    9.4. Market Value Forecast, by Distribution Channel, 2020-2034
        9.4.1. Hospital Pharmacies
        9.4.2. Retail Pharmacies
        9.4.3. Online Pharmacies
    9.5. Market Value Forecast, by Country, 2020-2034
        9.5.1. U.S.
        9.5.2. Canada
    9.6. Market Attractiveness Analysis
        9.6.1. By Drug Class
        9.6.2. By Distribution Channel
        9.6.3. By Country
10. Europe Polycystic Ovarian Syndrome Treatment Market Analysis and Forecast
    10.1. Introduction
    10.2. Key Findings
    10.3. Market Value Forecast, by Drug Class, 2020-2034
        10.3.1. Oral Contraceptives
        10.3.2. Antiandrogens
        10.3.3. Insulin-sensitizing Agent
        10.3.4. Antidepressant
        10.3.5. Anti-obesity
        10.3.6. Diuretics
        10.3.7. Others
    10.4. Market Value Forecast, by Distribution Channel, 2020-2034
        10.4.1. Hospital Pharmacies
        10.4.2. Retail Pharmacies
        10.4.3. Online Pharmacies
    10.5. Market Value Forecast, by Country/Sub-region, 2020-2034
        10.5.1. Germany
        10.5.2. U.K.
        10.5.3. France
        10.5.4. Italy
        10.5.5. Spain
        10.5.6. Rest of Europe
    10.6. Market Attractiveness Analysis
        10.6.1. By Drug Class
        10.6.2. By Distribution Channel
        10.6.3. By Country/Sub-region
11. Asia Pacific Polycystic Ovarian Syndrome Treatment Market Analysis and Forecast
    11.1. Introduction
    11.2. Key Findings
    11.3. Market Value Forecast, by Drug Class, 2020-2034
        11.3.1. Oral Contraceptives
        11.3.2. Antiandrogens
        11.3.3. Insulin-sensitizing Agent
        11.3.4. Antidepressant
        11.3.5. Anti-obesity
        11.3.6. Diuretics
        11.3.7. Others
    11.4. Market Value Forecast, by Distribution Channel, 2020-2034
        11.4.1. Hospital Pharmacies
        11.4.2. Retail Pharmacies
        11.4.3. Online Pharmacies
    11.5. Market Value Forecast, by Country/Sub-region, 2020-2034
        11.5.1. China
        11.5.2. Japan
        11.5.3. India
        11.5.4. Australia & New Zealand
        11.5.5. Rest of Asia Pacific
    11.6. Market Attractiveness Analysis
        11.6.1. By Drug Class
        11.6.2. By Distribution Channel
        11.6.3. By Country/Sub-region
12. Latin America Polycystic Ovarian Syndrome Treatment Market Analysis and Forecast
    12.1. Introduction
    12.2. Key Findings
    12.3. Market Value Forecast, by Drug Class, 2020-2034
        12.3.1. Oral Contraceptives
        12.3.2. Antiandrogens
        12.3.3. Insulin-sensitizing Agent
        12.3.4. Antidepressant
        12.3.5. Anti-obesity
        12.3.6. Diuretics
        12.3.7. Others
    12.4. Market Value Forecast, by Distribution Channel, 2020-2034
        12.4.1. Hospital Pharmacies
        12.4.2. Retail Pharmacies
        12.4.3. Online Pharmacies
    12.5. Market Value Forecast, by Country/Sub-region, 2020-2034
        12.5.1. Brazil
        12.5.2. Mexico
        12.5.3. Rest of Latin America
    12.6. Market Attractiveness Analysis
        12.6.1. By Drug Class
        12.6.2. By Distribution Channel
        12.6.3. By Country/Sub-region
13. Middle East & Africa Polycystic Ovarian Syndrome Treatment Market Analysis and Forecast
    13.1. Introduction
    13.2. Key Findings
    13.3. Market Value Forecast, by Drug Class, 2020-2034
        13.3.1. Oral Contraceptives
        13.3.2. Antiandrogens
        13.3.3. Insulin-sensitizing Agent
        13.3.4. Antidepressant
        13.3.5. Anti-obesity
        13.3.6. Diuretics
        13.3.7. Others
    13.4. Market Value Forecast, by Distribution Channel, 2020-2034
        13.4.1. Hospital Pharmacies
        13.4.2. Retail Pharmacies
        13.4.3. Online Pharmacies
    13.5. Market Value Forecast, by Country/Sub-region, 2020-2034
        13.5.1. GCC Countries
        13.5.2. South Africa
        13.5.3. Rest of Middle East & Africa
    13.6. Market Attractiveness Analysis
        13.6.1. By Drug Class
        13.6.2. By Distribution Channel
        13.6.3. By Country/Sub-region
14. Competition Landscape
    14.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
    14.2. Market Share Analysis, by Company (2023)
    14.3. Company Profiles
        14.3.1. Abbott Laboratories
            14.3.1.1. Company Overview
            14.3.1.2. Product Portfolio
            14.3.1.3. SWOT Analysis
            14.3.1.4. Financial Overview
            14.3.1.5. Strategic Overview
        14.3.2. AstraZeneca plc
            14.3.2.1. Company Overview
            14.3.2.2. Product Portfolio
            14.3.2.3. SWOT Analysis
            14.3.2.4. Financial Overview
            14.3.2.5. Strategic Overview
        14.3.3. Bayer AG
            14.3.3.1. Company Overview
            14.3.3.2. Product Portfolio
            14.3.3.3. SWOT Analysis
            14.3.3.4. Financial Overview
            14.3.3.5. Strategic Overview
        14.3.4. Bristol-Myers Squibb Company
            14.3.4.1. Company Overview
            14.3.4.2. Product Portfolio
            14.3.4.3. SWOT Analysis
            14.3.4.4. Financial Overview
            14.3.4.5. Strategic Overview
        14.3.5. Ferring B.V.
            14.3.5.1. Company Overview
            14.3.5.2. Product Portfolio
            14.3.5.3. SWOT Analysis
            14.3.5.4. Financial Overview
            14.3.5.5. Strategic Overview
        14.3.6. Merck KGaA
            14.3.6.1. Company Overview
            14.3.6.2. Product Portfolio
            14.3.6.3. SWOT Analysis
            14.3.6.4. Financial Overview
            14.3.6.5. Strategic Overview
        14.3.7. Novartis AG
            14.3.7.1. Company Overview
            14.3.7.2. Product Portfolio
            14.3.7.3. SWOT Analysis
            14.3.7.4. Financial Overview
            14.3.7.5. Strategic Overview
        14.3.8. Pfizer Inc.
            14.3.8.1. Company Overview
            14.3.8.2. Product Portfolio
            14.3.8.3. SWOT Analysis
            14.3.8.4. Financial Overview
            14.3.8.5. Strategic Overview
        14.3.9. Sanofi S.A.
            14.3.9.1. Company Overview
            14.3.9.2. Product Portfolio
            14.3.9.3. SWOT Analysis
            14.3.9.4. Financial Overview
            14.3.9.5. Strategic Overview
        14.3.10. Teva Pharmaceutical Industries Ltd.
            14.3.10.1. Company Overview
            14.3.10.2. Product Portfolio
            14.3.10.3. SWOT Analysis
            14.3.10.4. Financial Overview
            14.3.10.5. Strategic Overview
        14.3.11. Amneal Pharmaceuticals, Inc.
            14.3.11.1. Company Overview
            14.3.11.2. Product Portfolio
            14.3.11.3. SWOT Analysis
            14.3.11.4. Financial Overview
            14.3.11.5. Strategic Overview
        14.3.12. Laurus Labs
            14.3.12.1. Company Overview
            14.3.12.2. Product Portfolio
            14.3.12.3. SWOT Analysis
            14.3.12.4. Financial Overview
            14.3.12.5. Strategic Overview
        14.3.13. Zydus Pharmaceuticals (USA) Inc.
            14.3.13.1. Company Overview
            14.3.13.2. Product Portfolio
            14.3.13.3. SWOT Analysis
            14.3.13.4. Financial Overview
            14.3.13.5. Strategic Overview